Global cephalosporin drugs market is expected to reach $16.87 billion by 2027.
Global cephalosporin drugs market is valued approximately at $14.1 billion in 2020 and is anticipated to grow with a healthy growth rate of about 2.6% over the forecast period 2021-2027. Cephalosporin drugs refer to a group of semi-synthetic and wide-spectrum antibiotics which are majorly used in the treatment of bacterial infections such as kidney infections, pneumonia, meningitis, bone infections, sexually transmitted diseases (STDs), etc. The global cephalosporin drugs market is being driven by growing prevalence of infectious diseases and rising demand for anti-microbials in various indications. Furthermore, increase in research and development activities for the development of efficient and safe drugs will provide new opportunities for the global cephalosporin drugs industry. For instance, according to the American Association for the Advancement of Science, in 2021, a research team at the University of Texas had developed chemical probes for the identification of an enzyme which is produced by pneumococcal bacteriaand E. coli bacteria. The research also examined nutritional immunity which comes from the proteins produced by the human body in response to an infection. Also, in 2020, researchers from the University of Hong Kong discovered that infections caused by multidrug resistant superbugs (including pneumonia, bloodstream infections, wound infections, etc.) can be treated by reprocessing antirheumatic gold drug. Such research and development activities are expected to enhance the development of more efficient cephalosporin drugs to treat different bacterial infections and is expected to drive the market growth during the forecast period. However, side effects associated with cephalosporin may impede market growth over the forecast period of 2021-2027.

The regional analysis of the global cephalosporin drugs market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. Asia Pacific is the leading region across the world in terms of market share and is also anticipated to exhibit the highest growth rate over the forecast period 2021-2027due to factors such as easy availability of cephalosporin drugs, increased consumption of cephalosporin, increase in bacterial infection, rise in over-the-counter drugs sale, etc. in the region.

Major market player included in this report are:
Baxter International
F. Hoffmann-La Roche Ltd
GlaxoSmithKline PLC
Lupin Pharmaceuticals Inc.
Macleods Pharmaceuticals Ltd
Mankind Pharma
Merck & Co. Inc.
Pfizer Inc.
Teva Pharmaceutical Industries Ltd
Bristol-Myers Squibb Company

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Generation:
First-Generation Cephalosporin
Second-Generation Cephalosporin
Third-Generation Cephalosporin
Fourth-Generation Cephalosporin
Fifth-Generation Cephalosporin
By Prescription Type:
Prescription Drugs
OTC Drugs
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027.

Target Audience of the Global Cephalosporin Drugs Marketin Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors